Jul 02, 2024 8:30am EDT 180 Life Sciences Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
Mar 14, 2024 8:30am EDT 180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
Feb 26, 2024 7:00am EST 180 Life Sciences Corp. Announces 1-For 19 Reverse Stock Split as Part of Nasdaq Compliance Plan
Dec 04, 2023 9:00am EST 180 Life Sciences Engages Financial Advisor to Explore Strategic Alternatives
Aug 07, 2023 9:00am EDT 180 Life Sciences Announces an Agreement for a Clinical Pharmacology Study Testing a New Formulation of CBD for Enhanced Oral Uptake
Aug 03, 2023 8:00am EDT 180 Life Sciences Provides Update on Regulatory Approval Process in the UK and US for Dupuytren’s Disease Treatment; Continues Consultations with the UK MHRA and Initiates a Type C Meeting Request With the US FDA
Jul 31, 2023 8:00am EDT 180 Life Sciences Corp. Announces the Filing of a Provisional Patent Describing the Combination of CBD With GLP-1 Agonists to Suppress Appetite